Therapeutic drug monitoring of imatinib in paediatric chronic myeloid leukaemia: Data from a real‐world setting
British Journal of Haematology · 2025
DOI: 10.1111/bjh.20047 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Meinolf Suttorp und 8 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Hemato-Oncology, Medical Faculty, Technical University Dresden, Dresden, Germany. Hauptthemen laut MEDLINE: Imatinib Mesylate, Drug Monitoring, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Antineoplastic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sonnenstrahl e.V. Dresden-Förderkreis für krebskranke Kinder und Jugendliche, Verein Kaminkehrer helfen krebskranken Kindern, IZKF-Erlangen.
Abstract (Originalsprache)
Imatinib (IMA) therapy for paediatric chronic myeloid leukemia (pCML) requires age‐dependent dose adjustments. Assessment of therapeutic drug monitoring (TDM) under ‘real‐world’ conditions was performed. Collection of blood and TDM‐relevant data, calculation of individual dosage exposure, measurement of plasma C min (IMA, Nor‐IMA) by HPLC/MS‐MS and recording of adverse event (AE). Two hundred and forty‐six specimens from 66 patients were analysed. Individual median IMA dosage exposure was 253 mg/m 2 (range: 128–504). Children 1000 ng/mL with achieving OMR demonstrated in each 63% ( N = 24/37, N = 27/43, respectively) patients at months 3 and 6. In the cohort with lower levels, only 23% and 50%, respectively, achieved these milestones. This difference was significant only at month 3. Of 66 patients, 30 reported 125 AEs with gastrointestinal and musculoskeletal as leading complaints. In 9.3% of AEs, the correlated IMA C min was ≥3000 ng/mL. TDM is a simple and rapid additional tool for managing pCML under ‘real‐world conditions’.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pediatric Hemato-Oncology, Medical Faculty, Technical University Dresden, Dresden, Germany.
- Pediatric Oncology and Hematology, Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen, Erlangen, Germany.
- Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.
- Bavarian Cancer Research Center (BZKF), Erlangen, Germany.
- Pharmacy Department, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
- Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
ORCID-Profile: Meinolf Suttorp, Axel Karow, Manuela Krumbholz
Förderung
- Sonnenstrahl e.V. Dresden-Förderkreis für krebskranke Kinder und Jugendliche
- Verein Kaminkehrer helfen krebskranken Kindern
- IZKF-Erlangen
- Sächsische Landes- und Universitätsbibliothek (SLUB)
- Sächsische Landesbibliothek – Staats- und Universitätsbibliothek Dresden
Zitieren
APA
Suttorp, M., Sembill, S., Lensker, P., Hildebrand, V., Schirmer, E., Karow, A., Krumbholz, M., Rauh, M., & Metzler, M. (2025). Therapeutic drug monitoring of imatinib in paediatric chronic myeloid leukaemia: Data from a real‐world setting. British Journal of Haematology. https://doi.org/10.1111/bjh.20047
Vancouver
Suttorp M, Sembill S, Lensker P, Hildebrand V, Schirmer E, Karow A, et al. Therapeutic drug monitoring of imatinib in paediatric chronic myeloid leukaemia: Data from a real‐world setting. British Journal of Haematology. 2025. doi:10.1111/bjh.20047
BibTeX
@article{Suttorp2025,
author = {Suttorp, Meinolf and Sembill, Stephanie and Lensker, Phyllis and Hildebrand, Verena and Schirmer, Elke and Karow, Axel and Krumbholz, Manuela and Rauh, Manfred and Metzler, Markus},
title = {Therapeutic drug monitoring of imatinib in paediatric chronic myeloid leukaemia: Data from a real‐world setting},
journal = {British Journal of Haematology},
year = {2025},
doi = {10.1111/bjh.20047}
}
EUVIMED